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ABSTRACT
Objective: Costus pictus D. Don is a traditionally used plant in Naojan area of Golaghat district of Assam, 
India specifically for treating diabetes. Six compounds were isolated from standardized methanolic ex-
tract of the aerial parts (MECP). The prime objective was to select most potent antidiabetic compounds 
among the isolated compounds viz. F67, F12, F16, F3032, F37 & F48 by using in vitro and in vivo methods.
Methods: Isolated compounds were subjected to initial screening by in vitro α-amylase inhibition activity 
assay using iodine-starch and DNSA (3,5-dinitrosalicylic acid) methods. Compounds depicting promis-
ing in vitro activity were selected for in vivo Streptozotocin (STZ) induced antidiabetic screening activity. 
Then based on the in vivo results, most potent compounds were selected for instrumental characteriza-
tion by Q-TOF ESI-MS, 1HNMR, 13CNMR & FTIR.
Results: Amongst the six compounds isolated from MECP, three compounds viz. F12, F16 & F48 showed 
potent in vitro activity. They were subsequently subjected to evaluation of the antidiabetic activity in 
vivo by oral administration, at dose of 10, 20 & 50 mg/kg body weight respectively, using Wister rat 
(120-150 g) and Glibenclamide (10mg/k body weight) as standard. Two compounds, F12 and F48 at 
dose of 50 mg/kg body weight, reversed STZ induced diabetic parameters (increased blood glucose 
level, altered plasma profile and histoarchitecture of the pancreatic and hepatic cells) with statistical 
significance (P<0.05), that was comparable with the standard. Hence, instrumental characterization by 
Q-TOF ESI-MS, 1HNMR, 13CNMR & FTIR of compounds F12 and F48 isolated from MECP was carried 
out which established their identity as (3,5,7-Trihydroxy-3’-hydroxy-4’-methoxy) flavanone or [3,5,7-Tr-
ihydroxy-2-(3’-hydroxy-4’-methoxy phenyl)-2,3-dihydrochromen-4-one] and 3,5,8-trihydroxy-7-meth-
oxy-2-phenyl-2,3-dihydrochromen-4-one or [7-methoxy-3, 5, 8 trihydroxy flavanone] respectively.
Conclusion: The study culminated in elucidation of two flavanones as most potent compounds in ex-
hibiting antidiabetic activities. The findings were thus successful in validating the traditional practices 
in Golaghat district of Assam, India, associated with the use of Costus pictus D. Don in the treatment of 
diabetes.
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RESUMEN
Objetivo: Costus pictus D. Don es una planta usada tradicionalmente en la zona del distrito de Golaghat 
Naojan de Assam, India específicamente para el tratamiento de la diabetes. Seis compuestos se aislaron 
a partir de extracto metanólico estandarizados de las hojas (MECP). El principal objetivo fue seleccionar 
compuestos antidiabéticos más potentes entre los compuestos aislados viz. F67, F12, F16, F3032, F37 y 
F48 mediante métodos in vitro e in vivo.
Métodos: Los compuestos aislados fueron sometidos a cribado inicial mediante ensayo de actividad de 
inhibición in vitro α-amilasa utilizando yodo-almidón y métodos DNSA (ácido 3,5-dinitrosalicilico). Los 
compuestos que presentaban una actividad in vitro prometedora se seleccionaron para la actividad de 
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cribado antidiabético inducida por estreptozotocina (STZ) in vivo. 
En función de los resultados in vivo, la mayoría de los compuestos 
potentes se seleccionaron para la caracterización instrumental por 
Q-TOF ESI-MS, 1HNMR, 13CNMR y FTIR.
Resultados: Entre los seis compuestos aislados de MECP, tres com-
puestos viz. F12, F16 y F48 mostraron una potente actividad. Poste-
riormente se sometieron a evaluación de la actividad antidiabética 
in vivo mediante administración oral, en dosis de 10, 20 y 50 mg / 
kg peso, utilizando ratas Wister (120-150 g) y glibenclamida (10 
mg / kg peso) como estándar. Dos compuestos, F12 y F48 en dosis 
de 50 mg/kg peso, revirtieron los parámetros diabéticos inducidos 
por STZ (aumento del nivel de glucosa en sangre, plasma perfil 
alterado y histoarquitectura del páncreas y células hepáticas), con 
significación estadística (P<0,05) que era comparable con la nor-
ma. Se llevo a cabo la caracterización instrumental por Q-TOF 
ESI-MS, RMN 1H, RMN 13C y FTIR de los compuestos F12 y F48 
aislado de MECP, lo que estableció su identidad como (3,5,7-trihi-
droxi-3 ‘-hidroxi-4’- metoxi) flavanona o [3,5,7-trihidroxi-2- (fenil 
3 ‘-hidroxi-4’-metoxi) -2,3-dihydrochromen-4-ona] y 3,5,8-trihi-
droxi-7-metoxi -2-fenil-2,3-dihydrochromen-4-ona o [7-metoxi-3, 
5, 8 trihidroxi flavanona] respectivamente.
Conclusión: El estudio culminó en la elucidación de dos flavanon-
as como los compuestos más potentes en la exposición de activi-
dades antidiabéticas. Los resultados lograron validar las prácticas 
tradicionales en el distrito de Golaghat de Assam, India, asociados 
con el uso de Costus pictus D. Don en el tratamiento de la diabetes.
Palabras clave: Costus pictus; Actividad antidiabética; trihydroxy-
flavanone
INTRODUCTION
Costus pictus D. Don belongs to the genus Costus pertaining 
to the family Costaceae1. This plant is mainly distributed in 
the neo tropical regions2. In India it found in the sub-Him-
alayan tract from Himachal Pradesh to Arunachal Pradesh; 
and in the Western Ghats in Goa, Kerala and Tamil Nadu3. 
The presence of Costus pictus in Assam and its usage in tra-
ditional medicine is the first report by the authors from this 
part of India4. It is an erect plant, up to 3 meters high; root 
stock is tuberous; stem is sub-woody at the base. Leaves are 
elliptical and are spirally arranged around the stem. Leaf 
surface is firm and leathery. The primary bracts are borne 
on the inflorescence in spiral phyllotaxy. Flowers are yel-
low in colour with pink radiating stripes originating from 
the base. Flowering time in Indian condition is August to 
October.
Aerial parts of the plant are extensively used in Golaghat 
district of Assam by the traditional healers for the treat-
ment of diabetes4- 6.
The study was contemplated with the main objective of 
validation of the traditional usage and to identify most po-
tent antidiabetic compounds by using in vitro and in vivo 
methods.
MATERIALS AND METHODS
Reagents and Instruments Used
AR and GR grade reagent and chemicals purchased from 
Renkem, Hi Media, Merck, SRL etc. were used for perform-
ing different procedures in the study. Instruments like Bruk-
er FTIR, Leica DM 1000 Photomicroscope, Zeiss Projection 
Microscope, Lab India- UV-3200 UV Spectrophotometer 
etc. were used in different stages of the experimental study.
Collection of Plant Materials
Aerial parts of Costus pictus were collected from Naojan 
area of Golaghat district of Assam, India during the month 
of September-October.
Authentication of Plant Materials
Plant specimen herbariums were sent to Ministry of Envi-
ronment and Forests, Government of India, Botanical Sur-
vey of India, Eastern Regional Centre, Shillong, Meghalaya 
for authentication. The plant specimen was identified and 
confirmed as Costus pictus D. Don, Family: Costaceae by Dr. 
R.K. Singh, Scientist-D and HOD vide letter no. BSI/ERC/
Tech./2015-16.
Preliminary Processing of Plant Materials
The collected plant parts i.e. aerial parts of Costus pictus 
were washed thoroughly under running water to remove 
all adhering soil particles. After cleaning, the crude drug 
materials were dried under shed for about 6 week time. 
Then the crude drug materials were subjected to size re-
duction in a blender and packed in air tight containers for 
further study.
Isolation of Compounds from Standardized Plant Ex-
tracts
The dried crude drugs were extracted with methanol in 
Soxhlet apparatus. The methanolic extract of Costus pictus 
(MECP) was then subjected to column chromatography us-
ing Silica gel (120 mesh) as stationary phase for the isola-
tion of the phytoconstituents. The mobile phases used were 
in various ratios in increasing order of polarity, after repeat-
ed washing with DCM (dichloromethane) and petroleum 
ether to remove chlorophyll type impurities.
In vitro Screening of Compounds Based on Anti Dia-
betic Activity
α-amylase inhibition activity of isolated compounds were 
assayed to screen compounds with potent anti diabet-
ic property. Two methods viz. 3, 5-dinitrosalicylic acid 
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(DNSA) inhibition assay and Iodine-Starch method was 
used to do the screening.
DNSA Inhibition Assay Method
The α-amylase activity is measured using a colorimetric 
method with 3, 5-dinitrosalicylic acid (DNSA) reagent. In 
this method, starch is converted into maltose by α -amyl-
ase. Maltose released from starch is measured by the reduc-
tion of 3, 5-dinitrosalicylic acid. Maltose reduces the pale 
yellow coloured alkaline DNSA to orange- red colour. The 
intensity of the colour is proportional to the concentration 
of maltose present in the sample and is measured using a 
spectrophotometer at 540nm wavelength7.
Various concentrations (1, 2, 4, 8, 10 and 12 μg/ml) of com-
ponents, isolated from MECP were prepared in 10%DMSO8. 
0.5 ml of each concentration was added to 0.5 ml of 0.02M 
sodium phosphate buffer (pH 6.9 having 6mM sodium 
chloride) containing 0.04 unit of α-amylase and incubated 
at 37oC for 10 min. Then 0.5ml 1% starch solution prepared 
in 0.02M sodium phosphate buffer (pH 6.9) was added af-
ter which 1ml DNSA reagent was added to each and put 
in boiling water bath for 5min. After that the tubes were 
removed and allowed to cool to room temperature. 10ml 
distilled water was added and absorbance was measured 
at 540nm using UV-Visible spectrophotometer. The control 
was prepared by the same procedure but, without adding 
any sample. The results were expressed as % inhibition cal-
culated using the formula:
% inhibition = [(Acontrol – Atest) /Acontrol] ×100, Where, Acontrol = 
absorbance of the blank control (containing all reagents ex-
cept the test solution), Atest =absorbance of the test sample.
A percent inhibition versus concentration curve was then 
plotted and the concentration of sample required for 50% 
inhibition was determined and expressed as IC50 value.
Iodine Starch Method
The inhibition assay was performed according to Xiao et al 
(2006)9 using iodine-starch method. Various concentrations 
(1, 2, 4, 8, 10 and 12 μg/ml) of components, isolated from 
MECP were prepared in 10%DMSO8. 0.5 ml of each con-
centration was added to 0.5 ml of 0.02M sodium phosphate 
buffer (pH 6.9 having 6mM sodium chloride) containing 
0.04 unit of α –amylase and incubated at 37oC for 10 min. 
Then 0.5ml 1% starch solution prepared in 0.02M sodium 
phosphate buffer (pH 6.9) was added and incubated again 
at 37oC for 15 min. Then one drop of 1M HCl and 0.1 ml of 
iodine reagent (5mM I2 + 5mM KI) was added. Then 10ml 
distilled water was added and absorbance was measured 
at 620nm using UV-Visible spectrophotometer. The control 
was prepared by the same procedure but, without adding 
any sample. The results were expressed as % inhibition cal-
culated using the formula:
% inhibition = [(A control – Atest) /A control] ×100, Where, A control = 
absorbance of the blank control (containing all reagents ex-
cept the test solution), Atest =absorbance of the test sample.
A percent inhibition versus concentration curve was plot-
ted and the concentration of sample required for 50% inhi-
bition was determined and expressed as IC50 value.
In vivo Anti Diabetic Activity Study of Screened Com-
pounds
Based on the in vitro results the screened compounds were 
considered for in vivo evaluation of anti diabetic activity.
Toxicity Studies
The toxicity study was aimed at establishing the thera-
peutic index i.e. the ratio between the pharmacologically 
effective dose and the lethal dose, and also to perform the 
primary screening.
Toxicity studies were conducted for MECP as per protocol 
drawn under OECD guidelines 425 in female Wister rats. 
Limit test at 2000 mg/kg was conducted as per section 23 
of OECD guideline 425 and were found to be safe up to a 
dose of 2000 mg/kg body weight. Three dose levels were 
selected for the isolated compounds i.e. 10, 20 and 50 mg/
kg body weight (oral administration). based on the toxicity 
study.
Grouping of Animals
Healthy Wister rats weighing between 120-150 gm were se-
lected for performing the in vivo study. Animals were fed on 
standard laboratory diet with water ad libitum and housed 
in plastic cages at room temperature. The formulated diet 
contained corn flour, dry fish, wheat flour and multivita-
min syrup, which were mixed in equal ratio to form dough 
and then made into pellets and dried.
The duration for the experimentation procedure was three 
weeks.
Induction of Diabetes
Diabetes was induced in the rats by single intraperitonial 
injection (i.p.) of streptozotocin (STZ), prepared by dissolv-
ing in citrate buffer (pH 4.5), at a dose of 60 mg/kg body 
weight along with nicotinamide (NIC) at a dose of 120 
mg/kg body weight after overnight fasting. Animals with 
FBS≥200mg/dl were considered for the study.
Treatment Regimen of Experimental Animals
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Animals were treated accordingly as per the following reg-
imen:
1. 1. Group I: Normal Control, treated with vehicle i.e. 0.3% 
CMC (carboxy methyl cellulose) suspension at a dose of 
10 ml/kg body weight
2. 2. Group II: Negative Control, treated with STZ (60 mg/
kg body weight; i.p.) and NIC (120 mg/kg body weight; 
oral administration). Here, i.p. stands for intraperitonial 
route of administration.
3. 3. Group III: Standard, treated with (STZ+NIC)+Gliben-
clamide, (10 mg/kg body weight; oral administration)
4. 4. Group IV: Test Dose F12.1, F16.1, F48.1, treated with 
(STZ+NIC) +10mg/kg of compound F12, F16 and F48.
5. 5. Group V: Test Dose F12.2, F16.2, F48.2, treated with 
(STZ+NIC) +20mg/kg body weight; oral administration 
of compound F12, F16 and F48.
6. 6. Group VI: Test Dose F12.3, F16.3, F48.3, treated with 
(STZ+NIC) +50mg/kg body weight; oral administration 
of compound F12, F16 and F48.
Blood glucose level (FBS) and plasma lipid profile was ex-
amined on 1st, 7th, 14th and 21st day one hour after treatment. 
On the last day, one hour after the treatment animals were 
sacrificed followed by isolation of pancreas and liver for 
histopathological examination. The FBS was recorded us-
ing Accu-Chek ® Active blood glucose monitoring system.
Evaluation of Serum Biochemical Parameter
Blood was collected and allowed to stand for 20 min, and 
then centrifuged for 15-20 minutes at 2000 rpm to separate 
the serum and the latter was used for serum biochemical 
parameters (total cholesterol, triglycerides, ALT, AST and 
ALP).
Total Cholesterol Estimation
Total Cholesterol was estimated using CHOD/POD meth-
od10. The absorbance of the standard and test sample 
against blank was measured at a wavelength of 505 nm. 
Total Cholesterol content was then measured using the fol-
lowing formula,
Cholesterol (mg/dl) = (Abs. T/Abs. S) x 200 mg/dl; where 
T denotes test, S denotes standard and Abs denotes absorb-
ance. 200 mg/dl is the concentration of standard used.
Serum Triglyceride Estimation
Serum Triglyceride was estimated using GPO or GOD-
POD method11. The absorbance of the standard and test 
sample against blank was measured at a wavelength of 500 
nm. Triglycerides content was then measured using the fol-
lowing formula,
Triglycerides (mg/dl) = (Abs. T/Abs. S) x 200 mg/dl; where 
T denotes test, S denotes standard and Abs denotes absorb-
ance. 200 mg/dl is the concentration of standard used.
Serum ALT and AST Estimation
Serum ALT and AST were estimated at 370C by colorimetric 
method12 at 505 nm using 2, 4 DNPH. The enzyme activi-
ty was directly calculated from calibration curve prepared 
with standard.
Estimation of Serum ALP
Alkaline Phosphatase (ALP) is also measured using color-
imetric method13 at 507nm and 370C at an alkaline pH. The 
intensity of the colour is directly proportional to the activi-
ty of ALP present in the sample.
The enzyme activity was calculated using the following 
formula,
Total ALP activity in K.A. units = (Abs. T – Abs. C/ Abs. 
S – Abs. B) x 10 where T is test, C is control, S is standard, 
B is blank and Abs is absorbance. Conversion, 1K.A. unit 
= 7.1 U/L
Histopathological Studies
On the last day, one hour after the treatment, animals were 
sacrificed followed by isolation of pancreas and liver for 
histopathological examination. Isolated samples were pre-
served at 2-3°C with Bouin’s solution. For the histopatho-
logical examination samples were prepared using Rapid 
process. The samples were cut into thin ribbon using rotary 
microtome and strips placed in glass slides. These slides 
were then incubated overnight at a temperature of 37°C. 
After treatment with xylene and alcohol the slides were fi-
nally washed with water for 20min. The slides were stained 
with haematoxylin and eosin, after which it was fixed 
and observed under microscope (Leica Photomicroscope 
DM1000)14,15.
Instrumental Characterization of Selected Potent Compounds
The most potent compounds were selected for instrumen-
tal characterization followed by structure elucidation based 
upon the result generated after following in vitro and in vivo 
procedure as described above. 13C NMR, 1H NMR, FT-IR 
and MS spectral analysis was carried out for the potent 
compounds at Sophisticated Analytical Instrumentation 
Facility (SAIF), Punjab University, Chandigarh.
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RESULTS AND DISCUSSION
Extraction and Isolation of Compounds
The processed plant drug materials were subjected to hot 
extraction using methanol as solvent by Soxhlet apparatus. 
The extract so obtained was termed as methanolic extract of 
Costus pictus D. Don (MECP).
Column chromatography of MECP was performed using 
different solvent systems and a total of six compounds viz. 
F67, F12, F16, F3032, F37 and F48 were isolated after suita-
ble TLC characterization.
Screening of Compounds Based on In Vitro α-Amylase 
Inhibition Activity
DNSA Inhibition Assay
The DNSA inhibition assay was done according to the 
method of Miller et. al 7. The concentration of sample re-
quired for 50% inhibition was determined and expressed 
as IC50 value. Three compounds viz. F12, F16 and F48 ex-
hibited IC50 value of 10.16, 4.30 and 3.25 μg/ml respectively 
(Table 1).
Table 1. IC50 values of compounds isolated from MECP
*
Compounds
IC50 value (μg/ml)
(DNSA inhibition method)
IC50 value (μg/ml)
(Iodine-Starch method)
F67 -- --
F12 10.16 11.69
F16 4.30 8.90
F3032 -- --
F37 -- --
F48 3.25 5.57
*MECP is methanolic extract of Costus pictus D. Don
Iodine-Starch Method
The Iodine-Starch method was done according to the meth-
od of Xiao et. al 9. The concentration of sample required for 
50% inhibition was determined and expressed as IC50 val-
ue. Three compounds viz. F12, F16 and F48 exhibited IC50 
value of 11.69, 8.90 and 5.57 μg/ml respectively (Table 1).
Evaluation of In Vivo Anti Diabetic Activity of 
Screened Compounds
Streptozotocin induced diabetic rat model using three doses 
i.e. 10, 20 and 50 mg/kg body weight; oral administration, 
daily was used for in vivo antidiabetic activity evaluation. 
The in vivo study was approved by IAEC (Institutional An-
imal Ethical Committee) of Department of Pharmaceutical 
Sciences, Dibrugarh University, Dibrugarh, Assam-786004 
(Regd. No. 1576/GO/a/ 11/CPCSEA Dated: 17/02/2012 ) 
vide approval No: IAEC/DU/36 Dated: 03/12/2012. The 
fasting blood sugar of the experimental animals was meas-
ured on the 1st, 7th, 14th and 21st day of the study. The results 
are depicted in Table 2.
Serum Biochemical Parameter Evaluation
Serum biochemical parameters such as total cholesterol, 
triglyceride, AST, ALP and ALT levels were measured and 
tabulated in Table 3. The results so obtained were then sub-
jected to statistical analysis.
Histopathological Study
Histopathological studies on liver and pancreas obtained 
from animals belonging to different groups were conduct-
ed as per the above discussed procedure and are represent-
ed in Figure 1 and 2.
Different compounds isolated from MECP were found to 
alter the biomarker levels and the 50 mg/kg body weight; 
dose closely resembles to that of the standard group in suc-
cessfully controlling the elevated cholesterol and triglycer-
ide levels. Group F16.3 and F 48.3 treated with 50mg/kg 
animals significantly reversed the STZ induced diabetic pa-
rameters (increased blood glucose level, altered serum pro-
file and histoarchitecture of the pancreatic and hepatic cells) 
that is comparable with the standard drug. It can therefore 
be concluded that groups TDF12, TDF16 & TDF48 has sig-
nificant role in reversing altered lipid profile but the group 
TDF16 and 48, particularly at the dose 50mg/kg has been 
found to be more effective in successfully reversing the di-
abetic parameters induced by STZ. Hence, compounds F16 
and F48 isolated from MECP were considered for further 
instrumental characterization and structure elucidation.
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Table 2. Effects of different doses of compounds isolated from MECP on blood glucose levels in the treatment period
Animal Group
Blood glucose concentration in mg/dl
1st day 7th day 14th day 21st day
Group I
Normal Control
91.75
±2.59
93.49
±2.17
90.91
±3.54
92.55
±2.33
Group II
Negative Control
317.38
±14.94
323.65
±11.56###
319.71
±13.82###
321.85
±11.28###
Group III
Standard Treated
302.33
±18.51
231.54
±6.36***
186.58
±7.73***
143.21
±10.01***###
Group IV
Test Gr 1 
(10mg/kg)
F12.1
314.35
±13.42
287.16
±9.69***###
278.33
±8.31***###
268.14
±8.53***###
F16.1
309.78
±12.38
294.44
±10.30***###
286.82
±5.47***###
277.47
±7.41***###
F48.1
336.07
±18.66###
301.81
±10.16***###
278.38
±8.45***###
263.47
±9.55***###
Group V
Test Gr 2 
(20mg/kg)
F12.2
320.11
±12.73
277.92
±6.31***###
250.09
±4.19***###
237.32
±5.87***###
F16.2
311.71
±12.34
284.47
±7.46***###
267.54
±8.14***###
258.07
±9.83***###
F48.2
318.97
±11.07
281.53
±5.06***###
273.01
±7.43***###
266.52
±5.43***###
Group VI
Test Gr 3 
(50mg/kg)
F12.3
313.13
±9.36
268.77
±6.87***###
246.31
±8.55***###
213.61
±7.07***###
F16.3
308.07
±14.33
259.15
±4.88***###
236.61
±6.33***###
192.81
±3.41***###
F48.3
307.46
±15.60
233.84
±9.04***
197.74
±5.91***
157.12
±8.81***#
Values are expressed as mean ± SD (number of animals, n=6) significantly different at *p<0.1,**p<0.01, ***p<0.001 using Dunnett Com-
pare all vs negative control and at #p<0.1, ##p<0.01, ###p<0.001 using Dunnett Comapare all vs standard treated.
Table 3. Effects of different doses of compounds isolated from MECP on lipid profile and biochemical parameters in the treatment 
period
Animal Group
Triglyceride
(mg/dL)
Total Cholesterol
(mg/dL)
ALT
(U/L)
AST
(U/L)
ALP
(U/L)
Group I Normal 
Control
108.33±9.72 123.75±5.96 24.09±3.41 21.63±5.50 133.89±7.06
Group II Negative 
Control
489.75±16.13 ### 267.41±9.74### 68.11±7.34### 64.73±4.33### 177.54±8.93###
Group III Standard 
Treated
143.62±7.13*** 164.89±6.73*** 33.86±7.51***### 29.74±6.13*** 139.77±6.03***
Group IV
Test Gr1 
(10mg/
kg)
F12.1 238.14±11.03***### 263.17±4.79### 59.37±7.43### 53.32±6.19*### 151.54±9.44***
F16.1 211.39±6.74***### 234.63±8.34***### 53.73±8.11**### 56.75±7.27### 164.11±8.75*###
F48.1 156.57±6.31*** 189.91±3.17***### 50.61±7.29***## 42.59±6.26***## 141.45±5.31***
Group V
Test Gr 2 
(20mg/
kg)
F12.2 218.57±7.29***### 247.56±5.60***### 57.31±6.37*### 44.43±4.73***## 144.57±8.43***
F16.2 201.05±4.76***### 216.77±8.65***### 49.17±7.34***### 50.03±7.72**### 158.13±4.57***###
F48.2 143.91±3.4*** 181.89±7.75***## 45.75±4.63***# 39.01±6.23*** 143.57±6.31***
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Group VI
Test Gr 3
(50mg/
kg)
F12.3 187.53±9.23***### 238.91±6.13***### 54.07±6.35**### 41.71±3.74***# 131.08±8.48***
F16.3 179.11±6.15***### 202.03±11.44***### 46.16±4.78***# 43.28±6.16***## 140.54±6.11***
F48.3 151.13±4.89*** 173.755±1.04*** 39.61±3.12*** 27.43±9.11*** 133.71±7.91***
Values are expressed as mean ± SD (number of animals, n=6) significantly different at *p<0.1,**p<0.01, ***p<0.001 using Dunnett Com-
pare all vs negative control and at #p<0.1, ##p<0.01, ###p<0.001 using Dunnett Comapare all vs standard treated.
Figure 1. Photomicrograph (10X) of liver section treated with different test dose, standard drug, positive control and negative control 
groups.
a: Positive control group, administered with vehicle, b: Group treated with standard drug, c: Negative control group, Induced with 
Streptozotocin, d: Group treated at dose of 10 mg/kg body weight with F12, e: Group treated at dose of 20 mg/kg body weight with 
F12, f: Group treated at dose of 50 mg/kg body weight with F12, g: Group treated at dose of 10 mg/kg body weight with F16, h: Group 
treated at dose of 20 mg/kg body weight with F16, i: Group treated at dose of 50 mg/kg body weight with F16, j: Group treated at dose 
of 10 mg/kg body weight with F48, k: Group treated at dose of 20 mg/kg body weight with F48, l: Group treated at dose of 50 mg/kg 
body weight with F48.
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Figure 2. Photomicrograph (10X) of pancreas section treated with different test dose, standard drug, positive control and negative con-
trol groups.
a: Positive control group, administered with vehicle, b: Group treated with standard drug, c: Negative control group, Induced with 
Streptozotocin, d: Group treated at dose of 10 mg/kg body weight with F12, e: Group treated at dose of 20 mg/kg body weight with 
F12, f: Group treated at dose of 50 mg/kg body weight with F12, g: Group treated at dose of 10 mg/kg body weight with F16, h: Group 
treated at dose of 20 mg/kg body weight with F16, i: Group treated at dose of 50 mg/kg body weight with F16, j: Group treated at dose 
of 10 mg/kg body weight with F48, k: Group treated at dose of 20 mg/kg body weight with F48, l: Group treated at dose of 50 mg/kg 
body weight with F48.
23Ars Pharm. 2019; 60(1): 15-25
Characterization of potent antidiabetic compounds from Costus pictus D. Don found in Assam, India using in vitro in vivo methods
Instrumental Characterization of Selected Potent Com-
pounds
Based on the data generated from the in vivo studies con-
ducted on the compounds isolated from MECP, the com-
pounds F48 and F16 were found to be most potent, which 
can be comparable with that of the standard drug.
Spectral data obtained for compound F48 and F16 from dif-
ferent instrumental techniques are represented in Figure 3.
Figure 3. Instrumental characterization of compound F48 and F16.
a: Mass spectra of compound F48; b: Proton NMR spectra of compound F48; c: Carbon NMR spectra of compound F48; d: FTIR spectra 
of compound F48; e: Mass spectra of compound F16; f: Proton NMR spectra of compound F16; g: Carbon NMR spectra of compound 
F16; h: FTIR spectra of compound F16
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Structure Interpretation of Isolated Compounds
Compound F48
Compound F48 is pale yellow colored powder with a 
melting point range is 226-228 °C. Molecular formula of 
the compound F48 is deduced as C16H14O6 [(M+H+) peak 
at m/z 303.08]. The 1H NMR spectrum of displayed sig-
nals of two methine doublets at 5.17 (C-2) and 4.62 (C-3), a 
methoxy group at 3.82 and a hydroxyl group at 11.59(due to 
strong H-bonding). The 13CNMR spectrum of compound 
also displayed two methines at 82.9 (C-2) and 71.8(C-3), a 
methoxy group at 56.1 (OMe), a conjugated ketone at 198.3 
and the signals of two aromatic rings at137.3 (ring A) and 
127.0 (ring C) respectively. IR spectrum displayed absorp-
tion due to a chelated carbonyl which appeared at 1640 cm-1 
and a hydroxyl appeared at 3327 cm-1. This suggested that 
compound is a flavanone with an unsubstitued B ring with 
IUPAC name 3, 5, 9-trihydroxy-7-methoxy-2-phenyl-2,3-di-
hydrochromen-4-one or 3,5,8-trihydroxy-7-methoxy flava-
none. The structure is presented in Figure 3.
Compound F16
Compound F16 is light yellow colored powder with a melt-
ing point range is 225-226 °C. Molecular formula of the 
compound F16 is deduced as C16H14O7 [(M+H+) peak at 
m/z 318.07]. The 1H NMR spectrum of displayed signals 
of two methine doublets at 5.30 (s, 1H, aryl OH), 5.24 (d, 
1H, J=4 Hz, >CH-, C-2) and 5.10 (d, 1H, J=4 Hz, >CH-, C-3) 
and a methoxy group at 2.19 (s, 3H, OCH3; due to strong 
H-bonding). The 13CNMR spectrum of compound also dis-
played one methine at 70.04 (C-3, >CH-), a methoxy group 
at 56.20 (OMe), a conjugated ketone (>C=O, conj.) at 174.45 
and the signals of two aromatic rings at140.98 (aryl-C, ring 
A) and 120.27 (aryl-C, ring C) respectively. IR spectrum dis-
played absorption due to a chelated carbonyl (>C=O, conj.) 
which appeared at 1709.25 cm-1 and a hydroxyl group at 
3403.05 cm-1 (O-H, bonded), absorption due to methoxy 
appeared at 2921.74 cm-1, 2854.00 cm-1 (C-H, OCH3). This 
suggested that compound is a flavanone with an unsub-
stitued B ring with IUPAC name 3,5,7-Trihydroxy-2-(3’-hy-
droxy-4’-methoxy phenyl)-2,3-dihydrochromen-4-one or 
[(3,5,7-Trihydroxy-3’-hydroxy-4’-methoxy) flavanone]. The 
structure is presented in Figure 3.
CONCLUSION
Isolation of phytoconstituents from MECP was initiated 
using exhaustive column chromatography. Six compounds 
were successfully sequestered with the help of recolumn, 
purification and TLC characterization. Three of the six 
compounds viz. F12, F16 and F48 showed promising in vit-
ro results. IC50 values of compounds were taken into con-
sideration for selecting the potent compounds and two in 
vitro methods were performed i.e. DNSA inhibition assay 
and Iodine-Starch method. IC50 values of F12, F16 and F48 
were found to be 10.16, 4.30 and 3.25 μg/ml respectively as 
per DNSA inhibition assay and that by Iodine-Starch meth-
od were found to be 11.69, 8.9 and 5.57 μg/ml respectively. 
Compound F48 exhibited maximum activity followed by 
compound F16 and compound F12. Compounds F48, F16 
and F12 were therefore considered for in vivo anti diabetic 
activity using three dose regimens viz. 10, 20 and 50 mg/
kg body weight respectively. Compounds isolated from 
MECP were found to alter the biomarker levels and the 
50 mg/kg/ body weight dose closely resembles to that of 
the standard group in successfully controlling the elevated 
cholesterol and triglyceride levels. The groups F48.3 and 
F16.3, treated with 50mg/kg dose significantly reversed 
the STZ induced diabetic parameters (increased blood glu-
cose level, altered plasma profile and histoarchitecture of 
the pancreatic and hepatic cells), which is also evident from 
the histopathology data that is comparable with the stand-
ard drug. The compoundsF48 and F16 isolated from MECP 
were hence considered for further instrumental character-
ization for identification and validation of components re-
sponsible for the said biological activity. IUPAC name of 
the compounds were deduced based on different instru-
mental techniques and F48 was deduced as 3,5,9-trihy-
droxy-7-methoxy-2-phenyl-2,3-dihydrochromen-4-one or 
3,5,8-trihydroxy-7-methoxy flavanone and compound F16 
the IUPAC name was deduced as 3,5,7-Trihydroxy-2-(3’-hy-
droxy-4’-methoxy phenyl)-2,3-dihydrochromen-4-one or 
[(3,5,7-Trihydroxy-3’-hydroxy-4’-methoxy) flavanone].
The study findings were thus successful in identifying two 
flavanones as most potent compounds in exhibiting anti-
diabetic activities thereby validating the traditional belief 
associated with the use of Costus pictus D. Don.
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